Skip to main content

Day: January 10, 2022

Groundbreaking Study Reinforces Need for Increased Choline Supplementation During Pregnancy

New research from Cornell University finds that doubling recommended prenatal choline significantly improved childhood brain performance NEW HAMPTON, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) — In a new paper1 just published in The FASEB Journal, Cornell University researchers confirmed the critical role choline plays in infant cognitive development. This groundbreaking new research shows that pregnant women who took more than twice the recommended dose of choline during pregnancy had children that demonstrated significant cognitive benefits through early childhood. The original Cornell findings published in 20182 established that higher doses of choline during pregnancy led to improved cognitive performance in infant offspring. This new paper now highlights that cognitive improvements were both significant and enduring in those same...

Continue reading

CenExel Clinical Research Acquires California Neuroscience Research

Neurology & Psychiatry Facility in Los Angeles Joins the CenExel Centers of ExcellenceCenExel CNR DoctorDoctors at CenExel CNR Use State-of-the-art ResourcesSalt Lake City, Utah, Jan. 10, 2022 (GLOBE NEWSWIRE) — CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of California Neuroscience Research (“CenExel CNR”), a clinical research facility in Los Angeles with two decades of experience in neurological and psychiatric studies. The primary indications served by CenExel CNR include Alzheimer’s Disease, Depression, Anxiety, and Migraine. The acquisition of CenExel CNR further strengthens CenExel’s leading central nervous system (“CNS”) trial capabilities in the Neurology and Psychiatry therapeutic areas. CenExel CNR’s Los Angeles location also further expands the CenExel site network patient...

Continue reading

atai Life Sciences to Participate in Upcoming January Investor Conference

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference today:H.C. Wainwright BioConnect Conference (Virtual)Format: Fireside ChatDate and Time: Monday, January 10th, 2022, 2:00 p.m. ETWebcast Link: URLThe presentations and archived webcasts will also be accessible in the Events section of atai’s website. About atai Life Sciences atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently...

Continue reading

North Dallas Bank & Trust Co. Announces Fourth Quarter Earnings

DALLAS, Jan. 10, 2022 (GLOBE NEWSWIRE) — NDBT (North Dallas Bank & Trust Co.), an independent community bank established in 1961, today announced net earnings of $1,310,944 or $0.51 per share for the three months ending December 31, 2021, compared to $2,319,733 or $0.90 per share for the same period in 2020. Net earnings for the year ending December 31, 2021 totaled $7,111,980 or $2.77 per share, compared to $8,577,621 or $3.34 per share in 2020. Earnings were prepared internally without review by the company’s independent accountants. Financial results are the results of past performance, events and market conditions, and are not a guarantee for future results. Any forward-looking implications derived from this information may differ materially from actual results. Further information about the dividend declaration is available...

Continue reading

Total number of shares and voting rights at December 31, 2021

10 January 2022 Orange: information on the total number of shares and voting rights referred to in Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulations of the Autorité des Marchés Financiers. In application of Article L. 22-10-46 of the French Commercial Code (Code de commerce), as from 3 April 2016, a double voting right is automatically granted to fully paid-up shares that have been held in registered form and under a single shareholder name for at least two years.Date Number of shares Number of treasury shares without voting rights Theoretical number of voting rights [1] Number of voting rights exercisable01/31/2021 2, 660, 056,599 1, 350,099 3, 101, 508,888 3, 100, 158,78902/28/2021 2, 660, 056,599 1, 095,099 3, 101, 518,140 3, 100, 423,04103/31/2021 2, 660, 056,599 642,915 3,...

Continue reading

Luther Burbank Corporation Announces Fourth Quarter 2021 Earnings Release and Conference Call Dates

SANTA ROSA, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) — Luther Burbank Corporation (the “Company”) (NASDAQ: LBC), the holding company for Luther Burbank Savings (the “Bank”), announced today that it will release its financial results as of and for the quarter and year ended December 31, 2021 after the market closes on Tuesday, January 25, 2022. Simone Lagomarsino, President and Chief Executive Officer of Luther Burbank Corporation, and Laura Tarantino, Executive Vice President and Chief Financial Officer, will host a conference call on Wednesday, January 26, 2022 at 8:00 AM (PT) to discuss the Company’s results for the period. Analysts, investors, and the general public may listen to a discussion of the Company’s quarterly performance and a question/answer session by using the phone number or live webcast link listed below. The webcast...

Continue reading

Zoom Becomes the First Video Communications Client to Attain Common Criteria Certification

Issued by the German Federal Office for Information Security, the Certification Reinforces Zoom’s Commitment to Security SAN JOSE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) today announced that Zoom Meeting Client version 5.6.6 has become the first video communications client to attain certification for Common Criteria Evaluation Assurance Level 2 (v3.1 rev. 5), issued by the German Federal Office for Information Security (BSI). Common Criteria is an international standard for objectively evaluating that an IT product satisfies a defined set of security requirements. The evaluation involves analyzing a specific set of security targets, including guidance documentation, architectural design, life cycle aspects, testing and vulnerability assessment. The Zoom Meeting Client v5.6.6 has been...

Continue reading

MKS Withdraws from Photonics West 2022

ANDOVER, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) — MKS Instruments, Inc. (NASDAQ: MKSI) (“MKS”), a global provider of technologies that enable advanced processes and improve productivity, today announced that it has withdrawn from exhibiting at Photonics West 2022 in San Francisco. “The health and safety of our employees and customers is our top priority, and given the rapid rise in COVID-19 cases, we have made the difficult decision to withdraw from exhibiting at Photonics West 2022,” said John T.C. Lee, President and CEO of MKS. “We want to extend our thanks to the SPIE team for their work during these uncertain times, and we look forward to returning in 2023.” About MKS Instruments  MKS Instruments enables technologies that transform our world. We deliver technology solutions foundational to leading edge semiconductor manufacturing,...

Continue reading

Gold Line Announces Increased Financing of $4 Million and Inclusion of a Sprott Strategic Investor

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA VANCOUVER, British Columbia, Jan. 10, 2022 (GLOBE NEWSWIRE) — Gold Line Resources Ltd. (TSX-V: GLDL, Frankfurt: 4UZ, WKN: A2QGWC, OTCQB: TLLZF) (“Gold Line” or the “Company”) announces that it has amended the terms of the non-brokered private placement (the “Private Placement”) announced December 31, 2021. As part of the amended financing terms one or more members of the Sprott group of companies have agreed to act as finders in the Private Placement with respect to the sale of 18,750,000 Units, thereby increasing anticipated aggregate gross proceeds to $4 million. Under the amended terms of the Private Placement, subscribers may now purchase up to 25,000,000 units (the “Units”) at a price of $0.16 per Unit for aggregate proceeds...

Continue reading

AXT, Inc. Announces Formal Application for Subsidiary IPO

Company Also Increases Fourth Quarter 2021 Revenue Guidance FREMONT, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) — AXT, Inc. (NasdaqGS: AXTI), a leading manufacturer of compound semiconductor substrate wafers, today announced that its wafer manufacturing subsidiary in China, Beijing Tongmei Xtal Technology Co., Ltd. (“Tongmei”), has submitted to the Shanghai Stock Exchange, and the Shanghai Stock Exchange has accepted for review, a formal application to list Tongmei’s shares in an initial public offering (“IPO”) on the Shanghai Stock Exchange’s Sci-Tech innovAtion boaRd (the “STAR Market”). “This is a significant achievement and an important milestone for AXT,” said Morris Young, chief executive officer. “We founded Tongmei back in 1998. Since then, it has grown into a company that is engaged in the research, development, production...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.